semaglutide approval mash Wegovy Approved for MASH with Fibrosis | Preeti S. posted on the topic

As the role of #GLP1 therapies in #MASLD continues to grow, clinicians need clear guidance. A new Practice Guidance update in #HEPATOLOGY provides evidence-based recommendations on using semaglutide therapy for MASH, including

28.25

★★★★☆4.8 (126)

Diabetes Dialogue: FDA Approves Semaglutide (Wegovy) for MASH

20.37

★★★★★4.9 (98)

Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial

29.55

★★★★★5.0 (157)

Emerging Role of GLP-1 Receptor Agonists for the Treatment of MASH

21.65

★★★★★4.7 (84)

Scientific Poster: Resmetirom and Semaglutide in MASH Mouse Model Study

23.01

★★★★★4.9 (203)

Novo Nordisk has changed the GLP-1 narrative. Semaglutide (Wegovy) becoming the first FDA-approved GLP-1 therapy for MASH proves this is no longer only about weight loss. GLP-1s are evolving into broad metabolic

23.91

★★★★★5.0 (176)

The FDA has granted accelerated approval for Wegovy (semaglutide 2.4 mg, once‑weekly) to treat metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2–F3) without cirrhosis. This is standout

29.45

★★★★★4.8 (132)